N/A
Manufactured by ANI Pharmaceuticals, Inc.
28,632 FDA adverse event reports analyzed
Last updated: 2026-04-14
INSTALAX POLYETHYLENE GLYCOL 3350 is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ANI Pharmaceuticals, Inc.. The most commonly reported adverse reactions for INSTALAX POLYETHYLENE GLYCOL 3350 include DRUG INEFFECTIVE, INCORRECT PRODUCT ADMINISTRATION DURATION, OFF LABEL USE, NAUSEA, DIARRHOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for INSTALAX POLYETHYLENE GLYCOL 3350.
Out of 11,677 classified reports for INSTALAX POLYETHYLENE GLYCOL 3350:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 28,632 FDA FAERS reports that mention INSTALAX POLYETHYLENE GLYCOL 3350. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, INCORRECT PRODUCT ADMINISTRATION DURATION, OFF LABEL USE, NAUSEA, DIARRHOEA, CONSTIPATION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list ANI Pharmaceuticals, Inc. in connection with INSTALAX POLYETHYLENE GLYCOL 3350. Always verify the specific product and NDC with your pharmacist.